CLINUVEL Strategic Update II
Melbourne, Australia, 12 April 2021 CLINUVEL today announced its second Strategic Update,...
Read More
Media Release - CLINUVEL Expands DNA Repair Program
SCENESSE® (afamelanotide 16mg) to be evaluated in xeroderma pigmentosum variant (XP-V) CLINUVEL...
Read More
SCENESSE® To Be Evaluated in Xeroderma Pigmentosum Variant (XPV)
CLINUVEL today announced that it has reached agreement with clinical and academic...
Read More
SCENESSE® Granted Market Access In Israel
CLINUVEL today announced that SCENESSE® (afamelanotide 16mg) has been added to the...
Read More
H.C. Wainwright Bioconnect Conference 2021
12 January 2021 https://vimeo.com/clinuvel/review/499638631/b90c97ddb9 Download Presentation & Speaker Notes
Read More
Appendix 3G
Notification of issue, conversion or payment up of equity & securities. Download...
Read More
SCENESSE® DNA REPAIR STUDY IN HEALTHY VOLUNTEERS APPROVED
Melbourne, Australia, 30 November 2020 CLINUVEL PHARMACEUTICALS LTD today announced that it...
Read More
Jefferies Virtual London Healthcare Conference Presentation
20 November 2020 Download presentation & speaker’s notes
Read More
Chair's Letter To Shareholders
19 November 2020 Dear fellow shareholder, I look back at a year...
Read More
Results of Annual General Meeting
In accordance with Listing Rule 3.13.2 and section 251AA of the Corporations...
Read More
MANAGING DIRECTOR’S PRESENTATION TO CLINUVEL ANNUAL GENERAL MEETING
The following is a transcript of the Managing Director’s presentation to the...
Read More
CHAIR’S ADDRESS TO CLINUVEL ANNUAL GENERAL MEETING
I am up for re-election today, thank you for those who supported...
Read More
CLINUVEL Strategic Update – Executive Summary
CLINUVEL PHARMACEUTICALS LTD today released a strategic update on its business. An...
Read More